Redeye provides its first take on Oncopeptides' Q1 report 2025, published this morning. Sales grew 34% versus Q4 2024, a respectable number. Operating costs amounted to SEK-73m, an improvement from Q4, with an EBIT of SEK-61m. Overall, the quarter was in line with our expectations.
LÄS MER
